News PharmAbcine Inc.

Equities

A208340

KR7208340000

End-of-day quote Korea S.E. Other stock markets 23:00:00 18/01/2024 GMT			5-day change	1st Jan Change
2,915 ^KRW	-8.91%		-.--%	-22.27%

01-24	PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	CI
2023	PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology Annual Meeting 2024	04-23	AQ
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA in Patients with Advanced or Metastatic Solid Tumors	01-24	AQ
PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	01-24	CI
PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	12-25	CI
PharmAbcine Inc. announced that it has received KRW 30.000001149 billion in funding from Hpbiolab Inc.	11-30	CI
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data	11-10	AQ
Pharmabcine, Inc. Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-Related Macular Degeneration Following Dose Level 1 Safety Data	11-09	CI
PharmAbcine Inc. announced that it expects to receive KRW 5.000000492 billion in funding	25/10/23	CI
PharmAbcine Inc. announced extension to the offering period	06/08/23	CI
Yukon Partners Co., Ltd. acquired a 6.2% stake in PharmAbcine Inc. from Yoo Jin San for KRW 4.4 billion	26/07/23	CI
PharmAbcine Inc. announced that it expects to receive KRW 30.000001149 billion in funding	15/06/23	CI
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of its Novel TIE2 Agonistic Antibody in nAMD	23/05/23	CI
PharmAbcine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/03/23	CI
Pharmabcine Announces Collaboration Agreement with MSD to Evaluate Anti-Vista Antibody PMC-309 in Combination with Keytruda(R) (Pembrolizumab)	12/12/22	CI
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase 2023 during JPM Week	09/12/22	AQ
PharmAbcine Inc.(KOSDAQ:A208340) dropped from S&P Global BMI Index	19/09/22	CI
Pharmabcine Inc. Announces the Positive Results from the GLP Toxicology Study of PMC-403, the Company's Novel TIE2-Activating Antibody	26/04/22	CI
PharmAbcine Inc. Announces the Appointment of Quan Dong Nguyen to its Scientific Advisory Board	26/04/22	CI
PharmAbcine Inc. announced that it has received KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm	14/04/22	CI
PharmAbcine Inc. announced that it expects to receive KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm and other investors	12/04/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PharmAbcine Inc.

Equities

A208340

KR7208340000

Summary

Filters